Praxis Precision Medicines, Inc.
PRAX
Rang în acțiuni
#2615
Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the... Praxis Precision Medicines, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating innovative treatments for central nervous system (CNS) conditions that stem from an imbalance in neuronal activity. The company's primary investigational compounds currently undergoing evaluation include: PRAX-114, an extrasynaptic-preferring positive allosteric modulator of the GABAA receptor, which is currently in Phase IIa clinical trials for addressing both major depressive disorder and perimenopausal depression. Additionally, PRAX-944, a small molecule designed to selectively inhibit T-type calcium channels, is also progressing through Phase IIa clinical trials to manage essential tremor. Beyond these, Praxis is also advancing a pipeline of other promising drug candidates, such as: PRAX-562, a persistent sodium current blocker, undergoing Phase I clinical evaluation for treating severe pediatric epilepsy and adult cephalgia (headaches). PRAX-222, an antisense oligonucleotide (ASO) aimed at individuals suffering from gain-of-function (GOF) SCN2A epilepsy. And a program targeting KCNT1 for the treatment of KCNT1 GOF epilepsy. To further its research and development efforts, Praxis maintains several strategic alliances. These include a cooperation and licensing arrangement with RogCon Inc.; a licensing deal with Purdue Neuroscience Company; a comprehensive research collaboration, option, and license agreement with Ionis Pharmaceuticals, Inc.; and a collaborative project with The Florey Institute focused on the creation of three new antisense oligonucleotides (ASOs). Established in 2015, the company's headquarters are situated in Boston, Massachusetts.
Preț acțiune
$260.52
Ultima sincronizare: 2026-10-19
Capitalizare de piață
$7.27B
Schimbare (1 zi)
7.76%
Schimbare (1 an)
48.81%
Țară
US
Tranzacționează Praxis Precision Medicines, Inc. (PRAX)
Categorie
Healthcare
Câștiguri pentru Praxis Precision Medicines, Inc. (PRAX)
Câștiguri în Jun 2026 TTM: $-339.13M
Conform celor mai recente rapoarte financiare ale Praxis Precision Medicines, Inc., câștigurile actuale ale companiei sunt $-339.13M. În anul 2023, compania a înregistrat un câștig de $-123.28M, o creștere față de câștigului din 2022, care a fost de $-214.03M. Câștigurile afișate pe această pagină sunt cele înainte de dobânzi și impozite, cunoscute și ca EBIT.
Istoricul câștigurilor pentru Praxis Precision Medicines, Inc. din 2018 până în 2026
Câștiguri la sfârșitul fiecărui an
| An | Câștiguri | Schimbă |
|---|---|---|
| 2026 (TTM) | $-339.13M | 85.50% |
| 2024 | $-182.82M | 48.30% |
| 2023 | $-123.28M | -42.40% |
| 2022 | $-214.03M | 28.11% |
| 2021 | $-167.06M | 170.20% |
| 2020 | $-61.83M | 73.69% |
| 2019 | $-35.60M | 34.82% |
| 2018 | $-26.40M | 0.00% |
Câștiguri pentru companii similare sau concurente
| Companie | Câștiguri | Diferență de câștiguri | Țara |
|---|---|---|---|
| $5.27B | -1,655.44% |
US
|
|
| $-3.09B | 810.28% |
US
|
|
| $-4.02B | 1,084.28% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -675.20% |
NL
|
